Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812. - Di Caro V; Cho E; North HA; Caldwell J; Pandey K; Duong D; Grundman M; de Haan W; Vijverberg EG; Teunissen CE; Caggiano AO; Seyfried NT; et al. (Alzheimer's & dementia (New York, N. Y.), 2025)